Table 2.

Summary of non-compartmental LY3000328 plasma pharmacokinetic estimates

	Geometric mean (%CV geometric mean)
	LY3000328 1 mg	LY3000328 3 mg	LY3000328 10 mg	LY3000328 30 mg	LY3000328 100 mg	LY3000328 300 mg
n	6	6	6	6	6	6
Cmax	8.73	30.1	81.4	287	908	3870
(ng ml−1)	15	21	19	26	17	20
tmax*	4.05	3.04	3.05	3.53	4.05	2.05
(h)	(1.05–4.05)	(1.05–4.05)	(1.05–4.05)	(1.05–6.00)	(2.05–4.07)	(0.77–4.13)
t1/2†	4.68	5.16	5.80	7.62	5.65	5.96
(h)	(3.82–5.31)	(4.85–5.52)	(5.09–6.61)	(6.25–15.6)	(4.38–7.70)	(5.06–8.16)
AUC(0,∞)	72.8	231	830	2480	7990	24900
(ng ml−1 h)	7	15	10	18	16	15
AUC(0,24 h)	69.9	219	773	2280	7560	23700
(ng ml−1 h)	7	15	10	18	14	15
CL/F	13.7	13.0	12.0	12.1	12.5	12.0
(l h−1)	7	15	10	18	16	15
Vz/F	92.8	96.7	101	133	102	104
(l)	14	15	14	44	20	18

AUC(0,∞) = area under the concentration−time curve from time zero to infinite time; AUC(0,24 h) = area under the concentration−time curve from time zero to time 24 h; CL/F = apparent total body clearance of drug calculated after extra-vascular administration; C_max = maximum observed concentration; CV = coefficient of variation; n = number of subjects; t_max = time to maximum concentration; t_1/2 = half-life; V_z/F = apparent volume of distribution during the terminal phase after extra-vascular administration.

^*Median (range).

^†Geometric mean (range).